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Anti microbial screeningAbstract The 1-(6-chloro-2-methyl-4-phenylquinolin-3-yl)-3-(aryl)prop-2-en-1-ones were synthe-
sized by microwave assisted synthesis, the antimicrobial activities of synthesized compounds were
screened against Gram negative organisms such as Escherichia coli (ATCC 25922), Bacillus subtilis
(ATCC 117788), Salmonella typhi (ATCC 25264), Gram positive Staphylococcus aureus (ATCC
700699) and fungal organisms such as Aspergillus ﬂavus, Aspergillus fumigatus and Candida utilius.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Quinolines and their derivatives are very important because of
their biological activity (Muscia et al., 2006) and their wide
occurrence in natural products (Morimoto et al., 1991;
Michael, 1997). A large variety of quinolines displayed inter-
esting physiological activities and found to have attractive
applications in pharmaceuticals, agrochemicals as well as syn-
thetic building blocks (Markees et al., 1970; Campbell et al.,
1988; Maguire et al., 1994; Roma et al., 2000; Chen et al.,
2001). They are well-known structural unit in alkaloids, thera-peutics and synthetic analogues with interesting biological
activities such as antimalarial, antibacterial, antiasthmatic,
antihypertensive, anti-inﬂammatory and tyrokinase PDGF-
RTK inhibiting agents (Larsen et al., 1996; Roma et al.,
2000; Doube et al., 1998). Among quinolines chloroquine
remains a main antimalarial drug but the efﬁcacy of it and
other chemotherapeutic agents as meﬂoquine has been steadily
lessened by the spread of resistant parasites. Thus, the develop-
ment of alternative drugs is a continuing interest (Ayad et al.,
2001). Hence some of the derivatives of quinolines such as
quinolones have also been synthesised and they were also
examined for their biological activities (Siporin et al., 1990).
According to the literature information, it is apparent that
quinolones are potentiating the antifungal effect. Recently,
increased interest in combination therapy has also been devel-
oped (Brouillette et al., 2005; Nosanchuk, 2006). The efﬁcacy
of the newer quinolones in the treatment of nosocomial pneu-
monia is currently being assessed in clinical trials. Yet bacterial
resistance, relapse of infections and recurrent infections remain
Table 1 Physical data of compounds 3a–h.
S. No Ar Mp (C) Yield (%)
MWa
(time in min)
Conventional
method
3a 220–223 61(5) 68
3b 240–242 78(5) 75
3c 230–233 56(5) 60
3d 210–212 90(5) 87
3e 220–224 84(6) 85
3f 231–232 78(4) 79
3g 215–217 83(5) 80
3h 228–230 83(5) 76
a Power level at 240 W.
Scheme 1 Synthesis of 1-(6-chloro-2-methyl-4-phenylquinolin-3-
yl)-3-(aryl)prop-2-en-1-ones.
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to be a niche for this antibiotic class, these invites the explo-
ration of newer quinoline derivatives. We have reported
(Sarveswari and Raja, 2006) the microwave assisted synthesis
of some quinolone compounds. There are a few reports on syn-
thesis and biological studies of quinolinyl chalcones compared
to quinolones. In view of the above literature survey, herein we
report the synthesis, anti fungal and antibacterial activities of
newer quinolinyl chalcones.
2. Experimental
All the melting points reported were recorded in open capillar-
ies and uncorrected.
IR spectra of all the compounds were recorded on AVA-
TAR330 FT-IR Spectrometer. 1H NMR spectra were recorded
on Bruker AMX 300. The microwave assisted reactions were
carried out in synthetic microwave: CATA R with maximum
power of 700 W. The Mass spectra recorded on JEOL GC
mate spectrometer. Chemicals for microbial tests like agar
and broths were procured from Hi-Media Laboratories Ltd.,
Mumbai. Chemicals for the synthesis were from Sigma Aldrich
Co, St Louis, USA, and SD ﬁne chemicals Pvt. Ltd., Boisar,
India. Bacterial and Fungal culture from National Collection
of Industrial Microorganisms (NCIM), National Chemical
Laboratory Pune 411 008, Maharashtra, India.
2.1. General procedure for the synthesis of 1-(6-Chloro-2-
methyl-4-phenyl quinolin-3-yl)-(aryl) prop-2-en-1-ones (3a–h)
2.1.1. Method I (stirring at room temperature)
A mixture of compound 1 and arylaldehyde in 1:1 molar ratio
was added into a 2% solution of KOH in distilled ethanol and
stirred at room temperature for 12 h in a round bottom ﬂask.
Then the reaction mixture was concentrated and neutralized
with acetic acid. The resultant solid was ﬁltered, washed with
hot water, dried and puriﬁed by 7:1 mixture of petroleum
ether–ethyl acetate. Compound 1 was synthesized using litera-
ture method (Wang et al., 2006).
2.1.2. Method II (microwave assisted synthesis)
A mixture of compound 1 and pyridine-2-aldehyde in equimo-
lar ratio was added into a 2% solution of KOH in distilled eth-
anol taken in a beaker and irradiated with microwave at 240 W
for 5 min. The reaction mixture was cooled and poured onto
ice and acidiﬁed with acetic acid. The resultant solid was ﬁl-
tered, washed with sodium bicarbonate and water, dried and
puriﬁed by column using petroleum ether–ethyl acetate (7:1).
The procedure was extended to other arylaldehydes (2b–h) to
get the corresponding chalcones (3b–h) and thereby to prove
the generality of the reaction. The irradiation time, power
levels and the yield of the products are given in Table 1. All
the compounds were characterized by IR, 1H NMR and Mass
spectral data. The data are given in results and discussion.
The compounds are screened for their anti-microbial
activities.
3. Results and discussion
3-Acetyl-6-chloro-2-methyl-4-phenyl quinoline (1) has been
synthesized using the method (Wang et al., 2006) available inliterature which in turn converted into corresponding chal-
cones (3a–h) (see Scheme 1) by treating it with various aryl
aldehydes in the presence of base in ethanol under the micro
wave irradiation at 240 W for 4–6 min, whereas conventional
method requires 12 h of stirring. Completion of the reaction
was monitored by TLC, then the reaction mixture neutralized
with acetic acid, ﬁltered and dried. The obtained crude product
was puriﬁed through column chromatography using petroleum
ether–ethyl acetate (7:1).
The puriﬁed compounds 3a–h were characterized through
IR, 1H NMR and mass spectral studies. The stretching fre-
quencies at 1656 cm1 (due to a,b-unsaturated carbonyl) and
1565 cm1 (due to conjugated oleﬁnic C‚C) in IR conﬁrmed
the formation of expected products. The observed signal at d
2.70 (s, 3H, CH3) ppm integrating for three protons in
1H
NMR spectrum of 3a is due to the methyl group at C-2. The
signals at d 8.45 (d, 1H, 8 Hz), d 7.70 (d, 1H, 8.5 Hz), d 7.50
(s, 1H) ppm are due to protons at C-7, C-6 and C-5 of quino-
line ring. The protons of phenyl at C-4 observed as a multiplet
in the range of d 7.10–7.20 ppm. The protons of pyridine
Figure 4 Zone of inhibition by compounds (3a–h) on E. coli.
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characteristic peaks at d 8.05 (d, 1H, 15.7 Hz) and d 7.65 (d,
1H, 15.7 Hz) ppm represents cinnamoyl protons which are trans
to each other. The molecular ion peak at 384.3878 in ES-MS
also conﬁrmed the product 3a. Similarly the other compounds
3b–h also characterized (spectral data are given in Section 3).
The synthesized compounds 3a–h were screened for their anti
bacterial, anti-fungal activities through well diffusion method
using streptomycin and cephalosporin as respective standard.
All the synthesized compounds were found to have moderate
anti bacterial activity in comparison with standard streptomy-
cin (Figs. 1–4). The results revealed that the compound 3b, 3f
were showed good activity against Escherichia coli (E. coli).
Compounds 3e and 3c were active against Bacillus subtilis
(B. subtilis) 3a, 3e, 3g and 3b, 3d, 3f and 3h were found to be
active against Salmonella typhi (S. typhi) and Staphylococcus
aureus (S. aureus), respectively. In anti fungal screening, com-
pounds 3a, 3d–f were found to be active against Aspergillus ﬂa-
vus (A. ﬂavus), among these 3a has equivalent activity as the
standard cephalosporin. 3d, 3e and 3g were active against
Aspergillus fumigatus (A. fumigatus). The compounds 3b, 3e
and 3f were found to be active against candida utilis (C. utilis)Figure 1 Zone of inhibition by compounds (3a–h) on B. subtilis.
Figure 2 Zone of inhibition by compounds (3a–h) on S. typhi.
Figure 3 Zone of inhibition by compounds (3a–h) on S. aureus.among these 3e is very effective (Figs. 5–7) further studies are
required on active derivatives.
3.1. 1-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)-3-(pyridin-2-
yl)prop-2-en-1-one (3a)
Yellow solid, recrystallised from (1:4) petroleum ether–acetone
(Rf = 0.44). IR (KBr): 3615 (NH), 1656 (C‚O), 1565 (C‚C),Figure 5 Zone of inhibition by compounds (3a–h) on A. ﬂavus.
Figure 6 Zone of inhibition by compounds (3a–h) on A.
fumigatus.
Figure 7 Zone of inhibition by compounds (3a–h) on C. utilis.
Table 2a Mean zone of inhibition (mm) (3a–h) on B. subtilis
(ATCC 117788).
S. No Mean zone of inhibition (mm) and concentrations
50 lg/mL 100 lg/mL Std \ 100 lg/mL
3a – – 25
3b – – 25
3c 6 10 25
3d – – 25
3e 9 14 25
3f – – 25
3g – 8 25
3h 8 10 25
S38 S. Sarveswari, V. Vijayakumar1615 (C‚N) cm1; 1H NMR (400 MHz, CDCl3): d 8.45 (d,
1H, J= 8 Hz), d 7.70 (d, 1H, J= 8.5 Hz), d 7.50 (s, 1H), d
7.10–7.20 (m, 5H, Ar), d 7.30–7.45 (m, 4H, py), d 8.05 (d,
1H, J= 15.7 Hz, CH), d 7.65 (d, 1H, J= 15.7 Hz, CH)
ppm, ES-MS: 384.3878 [M]+.
3.2. 1-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)-3-(pyridine-3-
yl)prop-2-en-1-one (3b)
Yellow solid, recrystallised from (1:4) petroleum ether–acetone
(Rf = 0.42). IR (KBr): 3614 (NH), 1658 (C‚O), 1568 (C‚C),
1605 (C‚N) cm1; 1H NMR (400 MHz, CDCl3): d 2.60 (s,
3H, CH3), 7.30–7.50 (m, 4H, py), 7.10–7.30 (m, 4H, Ar),
7.70 (d, 1H, J= 15.6 Hz, CH), 8.05 (d, 1H, J= 15.4 Hz,
CH),. 8.50 (d, 1H, 8.2 Hz C7-Quinoline), 8.15 (m, 1H, C8-Quinoline)
7.60 (s, 1H, C
5-Quinoline
) ppm, ES-MS: 384.3878 [M]+.
3.3. 1-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)-3-(pyridine-4-
yl)prop-2-en-1-one (3c)
Yellow solid, recrystallised from (1:4) petroleum ether–acetone
(Rf = 0.44). IR (KBr): 3101 (NH), 1657 (C‚O), 1573
(C‚C),1605 (C‚N) cm1; 1H NMR (400 MHz, CDCl3): d
2.60 (s, 3H, CH3), 7.30–7.45 (m, 4H, py), 7.10–7.30 (m, 4H,
Ar), 7.70 (d, 1H, J= 15.6 Hz, CH), 8.05 (d, 1H,
J= 15.4 Hz, CH),. 8.50 (d, 1H, J= 8.2 Hz C7-Quinoline), 8.10
(m, 1H, C8-Quinoline) 7.50 (s, 1H, C5-Quinoline) ppm, ES-MS:
384.3875 [M]+.
3.4. 1-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)-3-(furan-2-
yl)prop-2-en-1-one (3d)
Pale yellow solid, recrystallised from (1:4) petroleum ether–
ethyl acetate (Rf = 0.47). IR (KBr): 3611 (NH), 1655
(C‚O), 1605 (C‚N) cm1; 1H NMR (400 MHz, CDCl3): d
2.60 (s, 3H, CH3), 7.30–7.45 (m, 4H, py), 7.10–7.30 (m, 4H,
Ar), 8.05 (d, 1H, J= 15.4 Hz, CH), 8.50 (d, 1H,
J= 15.6 Hz, CH), 7.60 (s, 1H, C5-Quinoline), 7.70 (d, 1H,
J= 8.2 Hz C8-Quinoline), 8.10 (m, 1H, C7-Quinoline) ppm. ES-
MS: 389.1503 [M]+.
3.5. 1, 4-(6-Chloro-2-methyl-4-phenyl quinolin-3-yl-3-oxo-prop-
1-enyl) benzene (3e)
Pale yellow solid, recrystallised from (1:4) petroleum ether–
ethyl acetate (Rf = 0.50). IR (KBr): 3434 (NH), 1683
(C‚O), 1550 (C‚C), 1606 (C‚N) cm1; 1H NMR
(400 MHz, CDCl3): d 2.58 (s, 3H), 8.05 (d, 1H,
J= 15.4 Hz), 7.69 (d, 1H, J= 15.4 Hz), 8.02 (d, 1H,
J= 8.7 Hz), 7.66 (dd, 1H, J= 8.9 Hz, 2.3 Hz), 7.53–7.58
(m, 6H), 7.27–7.36 (m, 5H) ppm. ES-MS: 383.1 [M]+.
3.6. 1-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)-3-(2-
chlorophenyl)prop-2-en-1-one (3f)
Pale yellow solid, recrystallised from (1:4) petroleum ether–
ethyl acetate (Rf = 0.56). IR (KBr): 3736 (NH), 1694
(C‚O), 1547 (C‚C), 1516 (C‚N) cm1; 1H NMR
(400 MHz, CDCl3): d 2.51 (s, 3H, CH3), 7.32–7.42 (m, 4H,
Ar), 6.60 (d, 2H, J= 8.6 Hz, Ar), 7.24 (d, 2H, Ar), 6.90 (d,1H, J= 16.2 Hz, CH), 6.30 (d, 1H, J= 16.2 Hz, CH). 8.10
(d, 1H, 4.2 Hz C5-Quinoline), 7.78 (m, 1H, C7-Quinoline), 7.42 (d,
1H, 8.2 Hz C8-Quinoline) ppm. ES-MS: 407 [M]
+.
3.7. 1-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)-3-(4-
methoxyphenyl)prop-2-en-1-one (3g)
Pale yellow solid, recrystallised from (1:4) petroleum ether–
ethyl acetate (Rf = 0.66). IR (KBr): 3607 (NH), 1636
(C‚O), 1593 (C‚C), 1507 (C‚N) cm1; 1H NMR
(400 MHz, CDCl3): d 2.57 (s, 3H, CH3), 3.78 (s, 3H, OCH3),
7.34–7.46 (m, 4H, Ar), 6.90 (d, 2H, J= 8.8 Hz, Ar (meta to
OCH3), 7.56 (d, 2H, Ar (ortho to OCH3), 7.20 (d, 1H,
J= 16.4 Hz, CH), 6.60 (d, 1H, J= 16.4 Hz, CH). 8.1 (d,
1H, J= 4.2 Hz C5-Quinoline), 7.85 (m, 1H, C7-Quinoline), 7.46
(d, 1H, J= 8.2 Hz C8-Quinoline) ppm. ES-MS: 401 [M]
+.
3.8. 1-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)-3-(4-
bromophenyl)prop-2-en-1-one (3h)
Pale yellow solid, recrystallised from (1:4) petroleum ether–
ethyl acetate (Rf = 0.54). IR (KBr): 3756 (NH), 1673
(C‚O), 1544 (C‚C), 1524 (C‚N) cm1; ES-MS: 407 [M]+.
1H NMR (500 MHz, CDCl3): d 2.69 (s, 3H, CH3), 7.39–7.43
(m, 3H, Ar), 7.28–7.30 (m, 5H, Ar), 7.24 (d, 1H, J= 5 Hz,
Ar), 7.04 (d, 1H, J= 17.5 Hz, CH), 6.54 (d, 1H,
J= 17.5 Hz, CH), 7.69 (dd, 1H, J= 10 Hz, 5 Hz, C7-Quinoline),
7.60 (d, J= 5 Hz, 1H, C
5-Quinoline
), 8.06 (d, 1H, J= 10 Hz
C8-Quinoline) ppm.
13C NMR (125 MHz, CDCl3): d 23.6
(CH3), 125.0, 126.0, 127.8, 128.6, 128.9, 129.3, 129.5, 129.9,
130.6, 131.0, 132.4, 132.5, 133.2, 134.5, 137.0, 144.6, 145.0,
146.2, 155.3, 196.9 (C‚O) ppm. ES-MS: 451 [M]+.
3.9. Antimicrobial screening
3.9.1. Measurement of minimum inhibitory concentration (MIC)
3.9.1.1. Media used. Muller Hinton broth and soboured dex-
trose broth from Himedia was used for bacteria and fungi,
respectively. All the culture was sterilized by autoclaving at
15 lbs for 20 min.
3.9.1.2. Broth dilution method. Exactly 1 mg/mL stock solution
of the synthesized compounds were made using DMSO as a
solvent. From the stock solutions required quantities of drug
solutions were mixed with the known quantities of the sterile
broth aseptically to provide the following concentrations
Table 2b Mean zone of inhibition (mm) (3a–h) on S. typhi
(ATCC 25264).
S. No Mean zone of inhibition (mm) and concentrations
50 lg/mL 100 lg/mL Std \ 100 lg/mL
3a 10 12 17
3b – 12 17
3c – 9 17
3d – – 17
3e 11 14 17
3f – 10 17
3g 8 13 17
3h 9 14 17
Table 2c Mean zone of inhibition (mm) (3a–h) on S. aureus
(ATCC 700699).
S. No Mean zone of inhibition (mm) and concentrations
50 lg/mL 100 lg/mL Std \ 100 lg/mL
3a 0 12 24
3b 12 14 24
3c 0 0 24
3d 8 12 24
3e – 9 24
3f 7 11 24
3g 8 13 24
3h 9 14 24
Table 2d Mean zone of inhibition (mm) (3a–h) on E. coli
(ATCC 25922).
S. No Mean zone of inhibition (mm) and concentrations
50 lg/mL 100 lg/mL Std \ 100 lg/mL
3a 0 0 22
3b 9 12 22
3c 7 8 22
3d 0 0 22
3e – 10 22
3f 0 6 22
3g 6 8 22
3h 6 8 22
Std \ Streptomycin (for anti bacterial screening).
Table 2e Mean zone of inhibition (mm) (3a–h) on A. ﬂavus.
S. No Mean zone of inhibition (mm) and concentrations
50 lg/mL 100 lg/mL Std \ 100 lg/mL
3a 9 15 16
3b – – 16
3c – – 16
3d – 8 16
3e – 8 16
3f 7 10 16
3g – – 16
3h – 8 16
Table 2f Mean zone of inhibition (mm) (3a–h) onA. fumigatus.
S. No Mean zone of inhibition (mm) and concentrations
50 lg/mL 100 lg/mL Std\100 lg/mL
3a – – 13
3b – – 13
3c – – 13
3d 10 11 13
3e – 8 13
3f – 9 13
3g 8 12 13
3h – 8 13
Table 2g Mean zone of inhibition (mm) (3a–h) on C. utilis.
S. No Mean zone of inhibition (mm) and concentrations
50 lg/mL 100 lg/mL Std\100 lg/mL
3a – – 20
3b 6 12 20
3c – – 20
3d 10 11 20
3e 7 14 20
3f 9 13 20
3g 5 7 20
3h 7 10 20
Std\Cephalosporin (anti-fungal screening).
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media containing the drug was dispensed into each sterile test
tube with 1 lL of standardized microorganism (1 · 105 CFU/
mL). After the inoculation all the tubes were incubated at
37 ± 1 C for 24 h and the growth of microorganisms ob-
served using optical density measurement. The lowest concen-
tration of test sample required to inhibit the growth of concern
bacteria was considered as Minimum Inhibitory Concentra-
tion (MIC). The MIC have been found for each compound
against various organisms such as E. coli (ATCC 25922), B.
subtilis (ATCC 117788), S. typhi (ATCC 25264), Gram posi-
tive S. aureus (ATCC 700699) by adopting the similar proce-
dure and are given in Tables 3a and 3b.
3.10. Antibacterial screening (well diffusion method)
A little of B. subtilis was added to the sterile Muller Hinton
broth medium at 45 C in aseptic environment and allowed
to grow for 24 h. A suspension of Muller Hinton agar was
transferred to sterile Perti dishes and allowed to solidify, then
a little of B. subtilis from the broth was applied uniformly on
the surface of solidiﬁed agar in sterile Perti dishes, in it wells of
6 mm diameter were made using well borer; speciﬁed concen-
tration of synthesized compounds and the standard were ap-
plied in these wells of agar plates in aseptic condition.
DMSO was used as control. Streptomycin was used as stan-
dard. All the plates were left for 1–4 h as a period of pre incu-
bation diffusion to minimize the effects of variation in time
between the applications of the different solutions. Then the
plates were incubated at 37 ± 1 C for 18–24 h. The diameter
of the zone of inhibition was measured for the plates in which
the zone of inhibition observed. The experiment was triplicated
to get reproducibility. Mean value for zone of inhibition was
Table 3a MIC values of compounds 3a–h for Bacterial organisms.
S. No MIC values lg and Name of the organism
Bacillus subtilis (ATCC
117788)
Staphylococcus aureus
(ATCC 700699)
Salmonella typhi
(ATCC 25264)
Escherichia coli (ATCC
25922)
3a 300 200 100 500
3b 400 200 100 100
3c 100 400 200 400
3d 300 100 300 300
3e 100 400 100 100
3f 400 100 100 300
3g 200 200 100 200
3h 100 100 100 200
Table 3b MIC values of compounds 3a–h for fungal
organisms.
S. No MIC values lg and Name of the organism
A. ﬂavus A. fumigatus C. utilis
3a 100 400 400
3b 400 300 100
3c 400 400 400
3d 200 100 100
3e 200 400 100
3f 100 300 100
3g 400 100 300
3h 300 400 100
S40 S. Sarveswari, V. Vijayakumarcalculated. A similar procedure was adopted to screen the anti-
bacterial activity of compounds 3b–h against E. coli, B. subtilis,
S. typhi, S. aureus. The measured zone of inhibitions (Figs. 1–
4) in mm were given in Tables 2a–d. The similar procedure was
adopted with soboured dextrose broth for antifungal screening
against A. ﬂavus, A. fumigatus, C. utilis. The plates were left for
1–4 h as a period of pre incubation diffusion to minimize the
effects of variation in time between the applications of the dif-
ferent solutions. Then the plates were incubated at 37 ± 1 C
for 24–28 h and then observed for antifungal activity. The
experiment was triplicated to get reproducibility, mean value
for zone of inhibition was calculated. The measured zone of
inhibitions (Figs. 5–7) in mm were given in Tables 2e–g.
4. Conclusion
1-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)-3-(aryl) prop-2-
en-1-ones were synthesised by microwave assisted method as
well as conventional method. When the reaction durations
were compared among microwave assisted synthesis (4–
6 min) and the conventional method (12 h), former method re-
quires much lesser duration with almost equal yield as in the
conventional method. Hence the microwave assisted synthesis
can be regarded as an efﬁcient method for the synthesis of
these compounds. All the synthesized compounds have been
screened for their anti microbial activities and are found to
be moderately active in comparison with standards. 3e has
shown good activity against B. subtilis. Compounds3e and
3h found to be effective against S. typhi. Similarly 3b, 3h acting
against S. aerues. In anti fungal screening, compounds 3a, 3d,
3e and 3f were found to be active against A. ﬂavus, among
these 3a has equivalent activity as the standard cephalosporin.The compounds 3b, 3e and 3f were found to be active against
C. utilis among these 3e is very effective. Further studies are
required on active derivatives.Acknowledgments
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